Amarin will receive an up front, ~$8M in event-related milestones & ~$4M in additional product-related milestones
CSL Seqirus will get exclusive license rights to Vazkepa from Amarin & will be responsible for market access and reimbursement efforts, distribution & commercialization of the product across Australia & New Zealand, Amarin will be responsible for supplying the finished product to CSL Seqirus in a profitable transfer price
Icosapent ethyl is approved & sold in Canada, Lebanon, and UAE in addition to the US under the brand name Vascepa. Vascepa’s marketing authorization has been granted in Great Britain in April 2021 & the therapy is currently approved and sold in the EU in Sweden, Denmark, Finland, Austria & the UK
Ref: Amarin | Image: Amarin
Related Post:- Amarin Reports (REDUCE-IT) Trial Results of Vascepa/Vazkepa (icosapent ethyl) for Cardiovascular Diseases
